Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TICE-strain BCG
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intravesical, Intradermal
01
Overview
TICE-strain BCG is an attenuated, live culture preparation of the Bacillus Calmette-Guérin (BCG) strain of Mycobacterium bovis, developed at the University of Illinois from a Pasteur Institute-originated strain. It is used both as an intravesical immunotherapy for non-muscle invasive bladder cancer and as a vaccine for tuberculosis prevention. For bladder cancer, it is administered directly into the bladder to induce a local immune response that targets tumor cells; its precise mechanism involves stimulating granulomatous inflammation and activating cellular immunity within the bladder wall. As a tuberculosis vaccine, it induces protective immunity against Mycobacterium tuberculosis infection[1][4][5][8]. The product contains live bacteria and must be handled with care in immunocompromised patients.
- Brand names
- TICE BCG
- Other names
- Bacillus Calmette-Guérin TICE strainBCG (TICE strain)Mycobacterium bovis BCG (TICE strain)
02
Targets
TLR2 (Toll-like Receptor 2)TLR9 (Toll-like receptor 9)TLR4 (Toll-like receptor 4)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)
Beyond the preview
Go deeper on TICE-strain BCG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TICE-strain BCG.